Isturisa (osilodrostat) — CareFirst (Caremark)
endogenous hypercortisolism in adult patients with Cushing’s syndrome for whom pituitary surgery is not an option or has not been curative
Initial criteria
- Diagnosis of Cushing’s syndrome/disease
- Member has had surgery that was not curative OR is not a candidate for surgery
- Pretreatment cortisol level documented by one of the following tests: Urinary free cortisol (UFC), Late-night salivary cortisol (LNSC), 1 mg overnight dexamethasone suppression test (DST), or Longer, low dose DST (2 mg per day for 48 hours)
Reauthorization criteria
- Lower cortisol levels since the start of therapy per one of the following tests: Urinary free cortisol (UFC), Late-night salivary cortisol (LNSC), 1 mg overnight dexamethasone suppression test (DST), or Longer, low dose DST (2 mg per day for 48 hours)
- OR Improvement in signs and symptoms of the disease
Approval duration
initial: 6 months; continuation: 12 months